Our collaborative projects  

Our approach to innovation is based on combining internal innovation programs and multidisciplinary, international, public and private collaborations with academic research institutions, the medical and scientific community, and cutting-edge biotech companies.

Joint research laboratories

In France

Since 2002, bioMérieux and the Lyon Civil Hospitals (HCL) have joined forces in two joint research laboratories within the Lyon Sud and Edouard Herriot Hospitals. They focus on three domains:

  • the diagnosis of severe bacterial infections among young children admitted to the Emergency Room or hospitalized in the neonatal ward;
  • the study of organ failure and kidney failure in particular, with a study of the NEPHROCHECK® test for the early risk assessment of acute kidney injuries among patients with multiple injuries, presenting a profile similar to that of patients with sepsis;
  • the validation of innovative tests for the characterization;
  • of the immune status of patients in intensive care.

In China

In early 2019, a new joint research laboratory was created with the Shanghai Children’s Medical Center (SCMC) as part of a three-year collaboration agreement.  Our work together began with a clinical study of the NEPHROCHECK® test for the early risk assessment of acute kidney injuries in young children following cardiac surgery.

Research projects and partnerships

In Brazil

Based on the model of the research program ANTOINE (bioMarkers to differeNtiate bacTerial frOm vIral iNfEctions) conducted in conjunction with the Lyon Civil Hospitals (HCL) in France, a collaboration with the Infants Institute of São Paulo focuses on the validation of biomarkers among immunocompromized and immuno-suppressed children with febrile illness for the diagnosis of severe bacterial infections. The aim of this project is to validate biomarkers that will guide the prescription of antibiotics.


In France with BIOASTER, the Technology Innovation Institute in Microbiology

  • A project project on rapid microbiology was launched to categorize bacteria using automated readers, an important step for the identification of pathogens.
  • A project enables to identified biomarkers for the diagnosis of tuberculosis and the prognosis of patients who are likely to develop active TB. Building on these results, bioMérieux will carry out a field validation study in 2020.
  • A project aims to develop on identification and the determination the resistance profile of bacteria in the context of sepsis, directly from blood samples.
  • A metagenomics project targeting hematologyoncology patients ended in 2019. Based on the genome sequencing of blood-borne viruses, this project led to the development of highly innovative know-how between BIOASTER and bioMérieux, which is amongst the world’s best teams for virome (the collection of all the genomes of a virus population, found in the same body or the same environment).

Public/private collaborations

bioMérieux participates in some projects within the scope of calls for tender in the European Union’s Horizon 2020 research and innovation program. The Company is the only partner from industry in the following consortia, designed to accelerate the clinical validation of new biomarkers and enlarge the scope of studies to develop prototypes for use on the BIOFIRE® FILMARRAY® and VIDAS® platforms.

  • The IMPACCT (IMmune Profiling of ICU Patients to address Chronic Critical illness and ensure healThy ageing) project involves several partners. Coordinated by bioMérieux in close collaboration with Imperial College London and the Lyon Civil Hospitals. The project's main objective is to validate the clinical performance of a panel of immune biomarkers in a study involving 800 patients with sepsis.
  • The DIAMONDS (Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis) project. The primary aim of this project is to develop a rapid test to distinguish viral from bacterial infections using a personalized genomic signature in cases of severe infection, especially in pediatric patients. The project, which is being coordinated by the Imperial College London, brings together 28 partners and 13 countries. DIAMONDS is the continuation of PERFORM, an on going European project, also funded through the Horizon 2020 program, in which bioMérieux is the only partner from industry.
  • ImmunoSep project coordinated by Radboud University Nijmegen Medical Center (the Netherlands), it will be the first large clinical study to demonstrate the efficacy of immunotherapy for the management of sepsis. Within the scope of this project, a European clinical network will be set up to allow the validation of future treatments and diagnostic tools. ImmunoSep will provide the first opportunity for bioMérieux to validate the biomarkers and tools developed through the REALISM project.



bioMérieux is the industry partner in the BRAINI (Blood biomarkers to improve management of mild traumatic brain injury) project, which was launched in 2019 with the support of EIT Health. This project assesses the performance of an automated blood test on the VIDAS® platform that measures two brain-specific proteins known to be elevated in patients who have intracranial lesions. It will also evaluates the prognostic value of the two brain biomarkers to detect patients at risk for deterioration of their neurological condition.


 Cooperation agreements with Entasis Therapeutics

  • According to the terms of an agreement this American biopharmaceutical company will make use of the BIOFIRE® FILMARRAY® systems and the Pneumonia and Pneumonia plus BIOFIRE® FILMARRAY® Panels for a phase 3 global clinical trial.
  • The trial aims to identify patients with pneumonia and septicemia caused by carbapenem-resistant Acinetobacter baumannii who are able to be treated by the antibiotic ETX-2514SUL.